Cargando…

Serological survey to estimate SARS-CoV-2 infection and antibody seroprevalence at a large public university: A cross-sectional study

OBJECTIVE: This study investigated the seroprevalence of SARS-CoV-2 antibodies among adults over 18 years. DESIGN: Prospective cohort study. SETTINGS: A large public university. PARTICIPANTS: This study took volunteers over 5 days and recruited 1064 adult participants. PRIMARY OUTCOME MEASURES: Sero...

Descripción completa

Detalles Bibliográficos
Autores principales: Hou, Ching-Wen, Williams, Stacy, Taylor, Kylee, Boyle, Veronica, Bobbett, Bradley, Kouvetakis, Joseph, Nguyen, Keana, McDonald, Aaron, Harris, Valerie, Nussle, Benjamin, Scharf, Phillip, Jehn, Megan L, Lant, Timothy, Magee, Mitchell, Chung, Yunro, LaBaer, Joshua, Murugan, Vel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10401225/
https://www.ncbi.nlm.nih.gov/pubmed/37536960
http://dx.doi.org/10.1136/bmjopen-2023-072627
_version_ 1785084611270803456
author Hou, Ching-Wen
Williams, Stacy
Taylor, Kylee
Boyle, Veronica
Bobbett, Bradley
Kouvetakis, Joseph
Nguyen, Keana
McDonald, Aaron
Harris, Valerie
Nussle, Benjamin
Scharf, Phillip
Jehn, Megan L
Lant, Timothy
Magee, Mitchell
Chung, Yunro
LaBaer, Joshua
Murugan, Vel
author_facet Hou, Ching-Wen
Williams, Stacy
Taylor, Kylee
Boyle, Veronica
Bobbett, Bradley
Kouvetakis, Joseph
Nguyen, Keana
McDonald, Aaron
Harris, Valerie
Nussle, Benjamin
Scharf, Phillip
Jehn, Megan L
Lant, Timothy
Magee, Mitchell
Chung, Yunro
LaBaer, Joshua
Murugan, Vel
author_sort Hou, Ching-Wen
collection PubMed
description OBJECTIVE: This study investigated the seroprevalence of SARS-CoV-2 antibodies among adults over 18 years. DESIGN: Prospective cohort study. SETTINGS: A large public university. PARTICIPANTS: This study took volunteers over 5 days and recruited 1064 adult participants. PRIMARY OUTCOME MEASURES: Seroprevalence of SARS-CoV-2-specific antibodies due to previous exposure to SARS-CoV-2 and/or vaccination. RESULTS: The seroprevalence of the antireceptor binding domain (RBD) antibody was 90% by a lateral flow assay and 88% by a semiquantitative chemiluminescent immunoassay. The seroprevalence for antinucleocapsid was 20%. In addition, individuals with previous natural COVID-19 infection plus vaccination had higher anti-RBD antibody levels compared with those who had vaccination only or infection only. Individuals who had a breakthrough infection had the highest anti-RBD antibody levels. CONCLUSION: Accurate estimates of the cumulative incidence of SARS-CoV-2 infection can inform the development of university risk mitigation protocols such as encouraging booster shots, extending mask mandates or reverting to online classes. It could help us to have clear guidance to act at the first sign of the next surge as well, especially since there is a surge of COVID-19 subvariant infections.
format Online
Article
Text
id pubmed-10401225
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-104012252023-08-05 Serological survey to estimate SARS-CoV-2 infection and antibody seroprevalence at a large public university: A cross-sectional study Hou, Ching-Wen Williams, Stacy Taylor, Kylee Boyle, Veronica Bobbett, Bradley Kouvetakis, Joseph Nguyen, Keana McDonald, Aaron Harris, Valerie Nussle, Benjamin Scharf, Phillip Jehn, Megan L Lant, Timothy Magee, Mitchell Chung, Yunro LaBaer, Joshua Murugan, Vel BMJ Open Epidemiology OBJECTIVE: This study investigated the seroprevalence of SARS-CoV-2 antibodies among adults over 18 years. DESIGN: Prospective cohort study. SETTINGS: A large public university. PARTICIPANTS: This study took volunteers over 5 days and recruited 1064 adult participants. PRIMARY OUTCOME MEASURES: Seroprevalence of SARS-CoV-2-specific antibodies due to previous exposure to SARS-CoV-2 and/or vaccination. RESULTS: The seroprevalence of the antireceptor binding domain (RBD) antibody was 90% by a lateral flow assay and 88% by a semiquantitative chemiluminescent immunoassay. The seroprevalence for antinucleocapsid was 20%. In addition, individuals with previous natural COVID-19 infection plus vaccination had higher anti-RBD antibody levels compared with those who had vaccination only or infection only. Individuals who had a breakthrough infection had the highest anti-RBD antibody levels. CONCLUSION: Accurate estimates of the cumulative incidence of SARS-CoV-2 infection can inform the development of university risk mitigation protocols such as encouraging booster shots, extending mask mandates or reverting to online classes. It could help us to have clear guidance to act at the first sign of the next surge as well, especially since there is a surge of COVID-19 subvariant infections. BMJ Publishing Group 2023-08-03 /pmc/articles/PMC10401225/ /pubmed/37536960 http://dx.doi.org/10.1136/bmjopen-2023-072627 Text en © Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Epidemiology
Hou, Ching-Wen
Williams, Stacy
Taylor, Kylee
Boyle, Veronica
Bobbett, Bradley
Kouvetakis, Joseph
Nguyen, Keana
McDonald, Aaron
Harris, Valerie
Nussle, Benjamin
Scharf, Phillip
Jehn, Megan L
Lant, Timothy
Magee, Mitchell
Chung, Yunro
LaBaer, Joshua
Murugan, Vel
Serological survey to estimate SARS-CoV-2 infection and antibody seroprevalence at a large public university: A cross-sectional study
title Serological survey to estimate SARS-CoV-2 infection and antibody seroprevalence at a large public university: A cross-sectional study
title_full Serological survey to estimate SARS-CoV-2 infection and antibody seroprevalence at a large public university: A cross-sectional study
title_fullStr Serological survey to estimate SARS-CoV-2 infection and antibody seroprevalence at a large public university: A cross-sectional study
title_full_unstemmed Serological survey to estimate SARS-CoV-2 infection and antibody seroprevalence at a large public university: A cross-sectional study
title_short Serological survey to estimate SARS-CoV-2 infection and antibody seroprevalence at a large public university: A cross-sectional study
title_sort serological survey to estimate sars-cov-2 infection and antibody seroprevalence at a large public university: a cross-sectional study
topic Epidemiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10401225/
https://www.ncbi.nlm.nih.gov/pubmed/37536960
http://dx.doi.org/10.1136/bmjopen-2023-072627
work_keys_str_mv AT houchingwen serologicalsurveytoestimatesarscov2infectionandantibodyseroprevalenceatalargepublicuniversityacrosssectionalstudy
AT williamsstacy serologicalsurveytoestimatesarscov2infectionandantibodyseroprevalenceatalargepublicuniversityacrosssectionalstudy
AT taylorkylee serologicalsurveytoestimatesarscov2infectionandantibodyseroprevalenceatalargepublicuniversityacrosssectionalstudy
AT boyleveronica serologicalsurveytoestimatesarscov2infectionandantibodyseroprevalenceatalargepublicuniversityacrosssectionalstudy
AT bobbettbradley serologicalsurveytoestimatesarscov2infectionandantibodyseroprevalenceatalargepublicuniversityacrosssectionalstudy
AT kouvetakisjoseph serologicalsurveytoestimatesarscov2infectionandantibodyseroprevalenceatalargepublicuniversityacrosssectionalstudy
AT nguyenkeana serologicalsurveytoestimatesarscov2infectionandantibodyseroprevalenceatalargepublicuniversityacrosssectionalstudy
AT mcdonaldaaron serologicalsurveytoestimatesarscov2infectionandantibodyseroprevalenceatalargepublicuniversityacrosssectionalstudy
AT harrisvalerie serologicalsurveytoestimatesarscov2infectionandantibodyseroprevalenceatalargepublicuniversityacrosssectionalstudy
AT nusslebenjamin serologicalsurveytoestimatesarscov2infectionandantibodyseroprevalenceatalargepublicuniversityacrosssectionalstudy
AT scharfphillip serologicalsurveytoestimatesarscov2infectionandantibodyseroprevalenceatalargepublicuniversityacrosssectionalstudy
AT jehnmeganl serologicalsurveytoestimatesarscov2infectionandantibodyseroprevalenceatalargepublicuniversityacrosssectionalstudy
AT lanttimothy serologicalsurveytoestimatesarscov2infectionandantibodyseroprevalenceatalargepublicuniversityacrosssectionalstudy
AT mageemitchell serologicalsurveytoestimatesarscov2infectionandantibodyseroprevalenceatalargepublicuniversityacrosssectionalstudy
AT chungyunro serologicalsurveytoestimatesarscov2infectionandantibodyseroprevalenceatalargepublicuniversityacrosssectionalstudy
AT labaerjoshua serologicalsurveytoestimatesarscov2infectionandantibodyseroprevalenceatalargepublicuniversityacrosssectionalstudy
AT muruganvel serologicalsurveytoestimatesarscov2infectionandantibodyseroprevalenceatalargepublicuniversityacrosssectionalstudy